KANGSTEM BIOTECH CO., LTD.
A stem cell therapeutics company developing umbilical cord blood-derived treatments for atopic dermatitis, rheumatoid arthritis, and osteoarthritis.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2015, KangStem Biotech develops and manufactures stem cell therapeutics. Based on its technology for high-purity isolation and mass culture of multipotent stem cells derived from human umbilical cord blood, its pipeline includes PURESTEM-AD (atopic dermatitis), PURESTEM-RA (rheumatoid arthritis), and OSCA (osteoarthritis, formerly PURESTEM-OA Kit). It also sells stem cell culture medium-based cosmetics and is developing exosome-based treatments for wounds/burns, pneumonia, and hair loss. Its bio-pharma division discontinued operations in the prior period, and its non-clinical testing division was deconsolidated following the sale of its stake in HLB Biocode (formerly Croen).
Products & technology
- GD stem cell culture medium cosmeticsCosmetics
- BIO stem cell culture medium-based functional shampooFunctional shampoo
Clinical trials
data.go.kr22 MFDS clinical trial authorisations · 2013–2025 (Extension 6 · Phase 1 6 · Phase 1/2a 5 · Phase 2b 2 · Phase 3 2)
- Extension퓨어스템-오에이 키트 주(FURESTEM-OA Kit Inj.)2025-12-10
7 trial sites
- Phase 2b퓨어스템-알에이주(FURESTEM-RA Inj.)2023-09-27
1 trial site
- Phase 1/2a퓨어스템-오에이 키트 주(FURESTEM-OA Kit Inj.)2022-11-15
7 trial sites
- Phase 3퓨어스템-에이디 주(FURESTEM-AD Inj.)2021-05-06
12 trial sites
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2019-07-15
2 trial sites
- Phase 1/2a퓨어스템-에이디 주(FURESTEM-AD Inj.)2019-07-08
2 trial sites
- Extension퓨어스템-알에이주(FURESTEM-RA Inj.)2019-04-05
7 trial sites
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2018-11-15
10 trial sites
- Phase 1동종제대혈유래중간엽줄기세포3주(hUCB-MSC3 Inj.)2018-05-14
1 trial site
- Phase 1/2a퓨어스템-알에이주(FURESTEM-RA Inj.)2018-02-19
7 trial sites
- Phase 3퓨어스템-에이디 주(FURESTEM-AD Inj.)2017-12-04
10 trial sites
- Phase 1동종제대혈유래중간엽줄기세포4주(hUCB-MSC4 Inj.)2017-10-10
1 trial site
Show 10 more
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-12-14
11 trial sites
- Phase 1동종제대혈유래중간엽줄기세포3주(hUCB-MSC3 Inj.)2016-10-17
1 trial site
- Phase 2b퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-07-14
6 trial sites
- Extension퓨어스템-알에이주(FURESTEM-RA Inj.)2016-05-09
1 trial site
- Phase 1/2a퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-04-18
1 trial site
- Phase 1퓨어스템-시디주(FURESTEM-CD Inj.)2015-08-10
1 trial site
- Phase 1퓨어스템-시디주(FURESTEM-CD Inj.)2014-12-31
1 trial site
- Phase 1퓨어스템-알에이주(FURESTEM-RA Inj.)2014-05-28
1 trial site
- Phase 1/2a퓨어스템-시디주(FURESTEM-CD Inj.)2013-06-10
4 trial sites
- Phase 1/2퓨어스템-에이디 주(FURESTEM-AD Inj.)2013-01-28
1 trial site
R&D and key agreements
Source: DART corporate disclosure퓨어스템-에이디 주 · 아토피피부염 · Umbilical cord blood-derived stem cell therapy pipeline
퓨어스템-알에이 주 · 류마티스관절염 · Umbilical cord blood-derived stem cell therapy pipeline
오스카(OSCA) · 골관절염 · Formerly named PURESTEM-OA Kit
창상(화상)치료제 · 창상, 화상 · Exosome-based therapeutics pipeline
폐렴치료제 · 폐렴 · Exosome-based therapeutics pipeline
탈모치료제 · 탈모 · Exosome-based therapeutics pipeline
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition